WASHINGTON, D.C.—The American Pharmacists Association (APhA) issued the following statement in response to the FTC’s stalemate 2-2 vote today, which would have supported study of the competitive impact of contractual provisions, reimbursement adjustments, and other PBM practices affecting drug prices, including those practices that may disadvantage independent or specialty pharmacies.

WASHINGTON, D.C.—The American Pharmacists Association (APhA) issued the following statement in response to plans and payers, including PBMs, setting the dispensing fee for new COVID‐19 oral antiviral therapies below pharmacies’ costs to dispense these lifesaving medications:

The American Pharmacists Association (APhA) and the American Society of Health-System Pharmacists (ASHP) today hailed the introduction of bipartisan legislation in the U.S. Senate that would give tens of millions of Medicare patients in medically underserved communities access to critically needed primary health care services delivered by pharmacists.